{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:58:44Z","timestamp":1791273524970,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.clinthera.2013.11.010","type":"journal-article","created":{"date-parts":[[2014,1,18]],"date-time":"2014-01-18T01:45:37Z","timestamp":1390009537000},"page":"292-306.e1","source":"Crossref","is-referenced-by-count":51,"title":["Systemic Antifungal Prophylaxis After Hematopoietic Stem Cell Transplantation: A Meta-Analysis"],"prefix":"10.1016","volume":"36","clinical-trial-number":[{"clinical-trial-number":"nct01200355","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01503515","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Panayiotis D.","family":"Ziakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene S.","family":"Kourbeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Mylonakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2013.11.010_bib1","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2012.66","article-title":"The EBMT activity survey: 1990-2010","volume":"47","author":"Passweg","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2013.11.010_bib2","first-page":"87","article-title":"report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders","volume":"2010","author":"Pasquini","year":"2010","journal-title":"Clin Transpl"},{"key":"10.1016\/j.clinthera.2013.11.010_bib3","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1002\/cncr.24507","article-title":"Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001\u20132007): stable incidence but changing epidemiology of a still frequently lethal infection","volume":"115","author":"Sipsas","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2013.11.010_bib4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/318483","article-title":"Aspergillosis case-fatality rate: systematic review of the literature","volume":"32","author":"Lin","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2013.11.010_bib5","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2013.11.010_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2013.11.010_bib7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/cid\/ciq147","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2013.11.010_bib8","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/bmt.2010.175","article-title":"European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3\u20142009 update","volume":"46","author":"Maertens","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2013.11.010_bib9","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.clinthera.2011.01.009","article-title":"Effectiveness of systemic antifungal prophylaxis in patients with neutropenia after chemotherapy: a meta-analysis of randomized controlled trials","volume":"32","author":"Ziakas","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2013.11.010_bib10","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.1200\/JCO.2007.12.3851","article-title":"Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis","volume":"25","author":"Robenshtok","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2013.11.010_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/323335","article-title":"Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus","volume":"34","author":"Ascioglu","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2013.11.010_bib12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.clinthera.2013.11.010_bib13","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.clinthera.2012.02.018","article-title":"Network analysis of randomized controlled trials in multiple sclerosis","volume":"34","author":"Zintzaras","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2013.11.010_bib14","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2013.11.010_bib15","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/sim.1201","article-title":"Network meta-analysis for indirect treatment comparisons","volume":"21","author":"Lumley","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.clinthera.2013.11.010_bib16","doi-asserted-by":"crossref","first-page":"b1147","DOI":"10.1136\/bmj.b1147","article-title":"Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews","volume":"338","author":"Song","year":"2009","journal-title":"BMJ"},{"issue":"7521","key":"10.1016\/j.clinthera.2013.11.010_bib17","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2013.11.010_bib18","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/TP.0b013e3182577485","article-title":"Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation","volume":"94","author":"Chaftari","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.clinthera.2013.11.010_bib19","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.bbmt.2012.03.014","article-title":"Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant","volume":"18","author":"Huang","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clinthera.2013.11.010_bib20","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08838.x","article-title":"Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation","volume":"155","author":"Marks","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2013.11.010_bib21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3349\/ymj.2011.52.2.293","article-title":"Efficacy of itraconazole prophylaxis for autologous stem cell transplantation in children with high-risk solid tumors: a prospective double-blind randomized study","volume":"52","author":"Kim","year":"2011","journal-title":"Yonsei Med J"},{"key":"10.1016\/j.clinthera.2013.11.010_bib22","first-page":"63","article-title":"[Cost benefit analysis for prophylactic use of itraconazole versus fluconazole after hematopoietic stem cell transplantation]","volume":"51","author":"Ota","year":"2010","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.clinthera.2013.11.010_bib23","doi-asserted-by":"crossref","first-page":"5111","DOI":"10.1182\/blood-2010-02-268151","article-title":"Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation","volume":"116","author":"Wingard","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2013.11.010_bib24","first-page":"1692","article-title":"[Comparison of micafungin and fosfluconazole as prophylaxis for invasive fungal infection during neutropenia in children undergoing chemotherapy and hematopoietic stem cell transplantation]","volume":"50","author":"Sawada","year":"2009","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.clinthera.2013.11.010_bib25","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s12185-008-0196-y","article-title":"Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation","volume":"88","author":"Hiramatsu","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clinthera.2013.11.010_bib26","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.clinthera.2008.04.020","article-title":"Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation","volume":"30","author":"Schonfeld","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2013.11.010_bib27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12185-007-0011-1","article-title":"Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation","volume":"87","author":"Hashino","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clinthera.2013.11.010_bib28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.11.010_bib29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/sj.bmt.1705418","article-title":"A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients","volume":"38","author":"Oren","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2013.11.010_bib30","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1128\/AAC.49.4.1331-1336.2005","article-title":"Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant","volume":"49","author":"Hiemenz","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2013.11.010_bib31","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2013.11.010_bib32","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1182\/blood-2003-08-2644","article-title":"Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants","volume":"103","author":"Marr","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2013.11.010_bib33","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-138-9-200305060-00006","article-title":"Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial","volume":"138","author":"Winston","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2013.11.010_bib34","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/ajh.10234","article-title":"Randomized trial of fluconazole versus low-dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation","volume":"71","author":"Koh","year":"2002","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clinthera.2013.11.010_bib35","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0002-9343(01)01127-5","article-title":"Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy","volume":"112","author":"MacMillan","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2013.11.010_bib36","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/sj.bmt.1702655","article-title":"Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination","volume":"26","author":"Trenschel","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2013.11.010_bib37","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/jac\/46.6.1001","article-title":"Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. The Canadian Fluconazole Study","volume":"46","author":"Laverdiere","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2013.11.010_bib38","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood.V96.6.2055","article-title":"Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial","volume":"96","author":"Marr","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2013.11.010_bib39","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/sj.bmt.1702233","article-title":"Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group","volume":"25","author":"Wolff","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2013.11.010_bib40","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1086\/313654","article-title":"A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients","volume":"30","author":"Nucci","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2013.11.010_bib41","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1046\/j.1365-2141.1999.01465.x","article-title":"A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. UK Multicentre Antifungal Prophylaxis Study Group","volume":"105","author":"Morgenstern","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2013.11.010_bib42","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj.bmt.1701543","article-title":"Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study","volume":"23","author":"Kelsey","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2013.11.010_bib43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1086\/515128","article-title":"Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group","volume":"28","author":"Rotstein","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2013.11.010_bib44","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1086\/515129","volume":"28","author":"Menichetti","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2013.11.010_bib45","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1079-2104(96)80328-3","article-title":"Prophylaxis of candidiasis in patients with leukemia and bone marrow transplants","volume":"81","author":"Epstein","year":"1996","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.clinthera.2013.11.010_bib46","first-page":"512","article-title":"Efficacy of different prophylactic antifungal regimens in bone marrow transplantation","volume":"80","author":"Annaloro","year":"1995","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2013.11.010_bib47","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/171.6.1545","article-title":"Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation\u2014a prospective, randomized, double-blind study","volume":"171","author":"Slavin","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2013.11.010_bib48","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0002-9343(94)90345-X","article-title":"The prophylactic use of low-dose amphotericin B in bone marrow transplant patients","volume":"97","author":"Riley","year":"1994","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2013.11.010_bib49","first-page":"1833","article-title":"Fungal prophylaxis with AmBisome in liver and bone marrow transplant recipients: results of two randomized double-blind studies","volume":"26","author":"Tollemar","year":"1994","journal-title":"Transplant Proc"},{"key":"10.1016\/j.clinthera.2013.11.010_bib50","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/jac\/33.2.309","article-title":"The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplantation Team","volume":"33","author":"Chandrasekar","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2013.11.010_bib51","first-page":"1495","article-title":"Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients","volume":"25","author":"Tollemar","year":"1993","journal-title":"Transplant Proc"},{"key":"10.1016\/j.clinthera.2013.11.010_bib52","first-page":"577","article-title":"Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients","volume":"12","author":"Tollemar","year":"1993","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2013.11.010_bib53","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/infdis\/165.5.891","article-title":"Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients","volume":"165","author":"Perfect","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.clinthera.2013.11.010_bib54","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJM199203263261301","article-title":"A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation","volume":"326","author":"Goodman","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.11.010_bib55","first-page":"127","article-title":"Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation? Results of a randomized placebo-controlled trial","volume":"7","author":"Benhamou","year":"1991","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2013.11.010_bib56","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.ijid.2011.10.004","article-title":"The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematicreview","volume":"16","author":"Garbati","year":"2012","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.clinthera.2013.11.010_bib57","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1128\/AAC.00428-11","article-title":"In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network","volume":"55","author":"Lockhart","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2013.11.010_bib58","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1128\/AAC.00597-13","article-title":"Amphotericin B+ and voriconazole+echinocandin combinations against Aspergillus spp.: effect of serum on inhibitory and fungicidal interactions","volume":"57","author":"Elefanti","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2013.11.010_bib59","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2013.11.010_bib60","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0149-2918(03)80125-X","article-title":"A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations","volume":"25","author":"Barrett","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2013.11.010_bib61","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1128\/AAC.01448-08","volume":"53","author":"Gubbins","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2013.11.010_bib62","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bmt.1705592","article-title":"High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation","volume":"39","author":"El-Cheikh","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2013.11.010_bib63","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbmt.2005.10.010","article-title":"High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study","volume":"12","author":"Mehta","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clinthera.2013.11.010_bib64","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1128\/AAC.00933-12","article-title":"Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens","volume":"56","author":"Hope","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2013.11.010_bib65","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/sj.bmt.1701270","article-title":"Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation","volume":"21","author":"Michallet","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clinthera.2013.11.010_bib66","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/jac\/36.4.657","article-title":"Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia","volume":"36","author":"Prentice","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2013.11.010_bib67","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2710.2001.00338.x","article-title":"Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics","volume":"26","author":"Willems","year":"2001","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2013.11.010_bib68","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.bbmt.2013.05.018","article-title":"Risk factors for invasive fungal disease after allogeneic hematopoietic stem cell transplantation: a single center experience","volume":"19","author":"Omer","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clinthera.2013.11.010_bib69","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2013.11.010_bib70","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3109\/13693786.2011.630040","article-title":"Impact of the revised (2008) EORTC\/MSG definitions for invasive fungal disease on the rates of diagnosis of invasive aspergillosis","volume":"50","author":"Tsitsikas","year":"2012","journal-title":"Med Mycol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813011272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291813011272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T09:12:49Z","timestamp":1597396369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291813011272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0149291813011272"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2013.11.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}